Expert view: Why you should use 3D models for high-throughput drug development screens

Posted: 10 September 2020 | | No comments yet

The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.

Although 2D monolayer assays have aided the registration of successful drugs, it is increasingly recognised that 2D assays do not model key aspects of the three-dimensional (3D) tumour environment. The adoption of high-throughput screening approaches using 3D assays to complement 2D approaches could therefore substantially improve the identification and clinical applicability of new cancer therapies.

    To read this expert view in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Horizon Discovery

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Related organisations